FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2854145802> ?p ?o ?g. }

• W2854145802 endingPage "669" @default.
• W2854145802 startingPage "654" @default.
• W2854145802 abstract "Despite significant advances in treatment, chronic lymphocytic leukaemia (CLL) remains an incurable disease. Ibrutinib and idelalisib, which inhibit Bruton Tyrosine kinase (BTK) and phosphoinositol-3 (PI3) kinase-δ respectively, have become important treatment options for the disease and demonstrate the potential of targeting components of the B-cell receptor-signalling pathway. IBL-202 is a dual inhibitor of the PIM and PI3 kinases. Synergy between the pan-PIM inhibitor, pPIMi, and idelalisib against a range of haematological cell lines and primary CLL cells supports the rationale for preclinical studies of IBL-202 in CLL. Importantly, IBL-202, but not idelalisib, was cytotoxic against CLL cells under in vitro conditions that mimic the hypoxic tumour microenvironment. The significant effects of IBL-202 on CD49d and CXCR4 expression and migration, cycle and proliferation of CLL cells suggest the drug may also interfere with the migratory and proliferative capacity of the leukaemic cells. Collectively, these data demonstrate that dual inhibition of the PIM and PI3 kinases by IBL-202 may be an effective strategy for targeting CLL cells, particularly within the environmental niches known to confer drug-resistance." @default.
• W2854145802 created "2018-07-19" @default.
• W2854145802 creator A5003114639 @default.
• W2854145802 creator A5004676114 @default.
• W2854145802 creator A5009840054 @default.
• W2854145802 creator A5016929277 @default.
• W2854145802 creator A5021890261 @default.
• W2854145802 creator A5069862870 @default.
• W2854145802 creator A5087985272 @default.
• W2854145802 date "2018-07-05" @default.
• W2854145802 modified "2023-10-16" @default.
• W2854145802 title "The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment" @default.
• W2854145802 cites W1490240498 @default.
• W2854145802 cites W1604058700 @default.
• W2854145802 cites W1786044410 @default.
• W2854145802 cites W1966176383 @default.
• W2854145802 cites W1966988306 @default.
• W2854145802 cites W1967320533 @default.
• W2854145802 cites W1969953749 @default.
• W2854145802 cites W1973500525 @default.
• W2854145802 cites W1979834961 @default.
• W2854145802 cites W1990418094 @default.
• W2854145802 cites W1994740077 @default.
• W2854145802 cites W2001850157 @default.
• W2854145802 cites W2003936694 @default.
• W2854145802 cites W2007019182 @default.
• W2854145802 cites W2009593167 @default.
• W2854145802 cites W2015969861 @default.
• W2854145802 cites W2019655196 @default.
• W2854145802 cites W2021381932 @default.
• W2854145802 cites W2024014530 @default.
• W2854145802 cites W2026384230 @default.
• W2854145802 cites W2049882979 @default.
• W2854145802 cites W2054719244 @default.
• W2854145802 cites W2058645214 @default.
• W2854145802 cites W2058677153 @default.
• W2854145802 cites W2067064694 @default.
• W2854145802 cites W2068962767 @default.
• W2854145802 cites W2075162479 @default.
• W2854145802 cites W2077945404 @default.
• W2854145802 cites W2082075917 @default.
• W2854145802 cites W2095447519 @default.
• W2854145802 cites W2103935957 @default.
• W2854145802 cites W2110386073 @default.
• W2854145802 cites W2111803606 @default.
• W2854145802 cites W2120712298 @default.
• W2854145802 cites W2124923311 @default.
• W2854145802 cites W2136628513 @default.
• W2854145802 cites W2149787043 @default.
• W2854145802 cites W2171218023 @default.
• W2854145802 cites W2172215449 @default.
• W2854145802 cites W2185820237 @default.
• W2854145802 cites W2195033221 @default.
• W2854145802 cites W2204695292 @default.
• W2854145802 cites W2233614027 @default.
• W2854145802 cites W2260144678 @default.
• W2854145802 cites W2263583556 @default.
• W2854145802 cites W2306967734 @default.
• W2854145802 cites W2337485820 @default.
• W2854145802 cites W2338436382 @default.
• W2854145802 cites W2399745303 @default.
• W2854145802 cites W2409557040 @default.
• W2854145802 cites W2424625022 @default.
• W2854145802 cites W2469555883 @default.
• W2854145802 cites W2479187350 @default.
• W2854145802 cites W2500616406 @default.
• W2854145802 cites W2532772806 @default.
• W2854145802 cites W2536094308 @default.
• W2854145802 cites W2563723939 @default.
• W2854145802 cites W2563802875 @default.
• W2854145802 cites W2566053885 @default.
• W2854145802 cites W2574311338 @default.
• W2854145802 cites W2580821712 @default.
• W2854145802 cites W2587889947 @default.
• W2854145802 cites W2594646846 @default.
• W2854145802 cites W51210568 @default.
• W2854145802 doi "https://doi.org/10.1111/bjh.15447" @default.
• W2854145802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29978459" @default.
• W2854145802 hasPublicationYear "2018" @default.
• W2854145802 type Work @default.
• W2854145802 sameAs 2854145802 @default.
• W2854145802 citedByCount "12" @default.
• W2854145802 countsByYear W28541458022019 @default.
• W2854145802 countsByYear W28541458022020 @default.
• W2854145802 countsByYear W28541458022021 @default.
• W2854145802 countsByYear W28541458022022 @default.
• W2854145802 crossrefType "journal-article" @default.
• W2854145802 hasAuthorship W2854145802A5003114639 @default.
• W2854145802 hasAuthorship W2854145802A5004676114 @default.
• W2854145802 hasAuthorship W2854145802A5009840054 @default.
• W2854145802 hasAuthorship W2854145802A5016929277 @default.
• W2854145802 hasAuthorship W2854145802A5021890261 @default.
• W2854145802 hasAuthorship W2854145802A5069862870 @default.
• W2854145802 hasAuthorship W2854145802A5087985272 @default.
• W2854145802 hasBestOaLocation W28541458021 @default.
• W2854145802 hasConcept C184235292 @default.
• W2854145802 hasConcept C203014093 @default.
• W2854145802 hasConcept C2776107976 @default.

• next